Tyrosine Phosphatase PTPRO Deficiency in ERBB2-Positive Breast Cancer Contributes to Poor Prognosis and Lapatinib Resistance

• Egile Nagusiak: Hongmei Dong (Egilea), Liang Du (Egilea), Songwang Cai (Egilea), Wan Lin (Egilea), Chaoying Chen (Egilea), Matthew Still (Egilea), Zhimeng Yao (Egilea), Robert P. Coppes (Egilea), Yunlong Pan (Egilea), Dianzheng Zhang (Egilea), Shegan Gao (Egilea), Hao Zhang (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Despite the initial benefit from treating ERBB2-positive breast cancer with tyrosine kinase inhibitor lapatinib, resistance develops inevitably. Since the expression of protein tyrosine phosphatase receptor-type O (PTPRO), a member of the R3 subfamily of receptor protein tyrosine phosphatases (PTPs)...